Soleno Therapeutics Announces Peer-Reviewed Publication Of Results From Long-Term Open-Label Study Of DCCR In Prader-Willi Syndrome
Portfolio Pulse from Benzinga Newsdesk
Soleno Therapeutics (NASDAQ:SLNO) has published one-year results from the Phase 3 DESTINY PWS study and the open-label extension period of Study C602, evaluating DCCR (Diazoxide Choline) Extended-Release tablets for patients with Prader-Willi syndrome (PWS). The study demonstrated significant, sustained reductions in hyperphagia, a chronic feeling of insatiable hunger that severely diminishes the quality of life for PWS patients. Soleno anticipates submitting an NDA to the FDA for DCCR in mid-2024.
November 06, 2023 | 1:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Soleno Therapeutics has published positive results from a long-term study of DCCR for treating Prader-Willi syndrome. The company plans to submit an NDA to the FDA in mid-2024.
The positive results from the long-term study of DCCR for treating Prader-Willi syndrome are a significant milestone for Soleno Therapeutics. This could potentially lead to FDA approval and commercialization of the drug, which would have a positive impact on the company's revenues and profitability. Therefore, this news is likely to have a positive impact on Soleno's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100